This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Should John Hancock Multifactor Mid Cap ETF (JHMM) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for JHMM
Edwards Lifesciences Presents Positive Partner 3 Trial Data
by Zacks Equity Research
Edwards Lifesciences (EW) expects SAPIEN 3 to gain FDA approval for the low-risk indication in late-2019.
Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus
by Zacks Equity Research
Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus
NASH, Allergies and Beauty Stocks: Invest or Not?
by Tracey Ryniec
There's a lot of innovation going on at the biopharmaceutical companies but which areas should investors be targeting?
Medtronic (MDT) Releases Encouraging Evalut TAVR Result
by Zacks Equity Research
Medtronic's (MDT) clinical study data shows that the low-risk aortic stenosis patients have special characteristics as they tend to be younger and active compared with the higher-risk equivalents.
Edwards Lifesciences (EW) Looks Good: Stock Adds 6.2% in Session
by Zacks Equity Research
Edwards Lifesciences (EW) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Company News For Mar 19, 2019
by Zacks Equity Research
Companies in the news are: OSTK, FIS, WP, EW and DERM
Edwards Lifesciences Makes Investments in Heart Failure Space
by Zacks Equity Research
The two transactions align with Edwards Lifesciences' (EW) goal of making the most innovative medical care available to patients of structural heart disease.
Edwards Lifesciences to Buy CASMED to Boost Critical Care Arm
by Zacks Equity Research
The CASMED buyout is expected to strengthen Edwards Lifesciences' (EW) position in smart monitoring technologies and boost top-line contributions from the Critical Care arm.
Should John Hancock Multifactor Mid Cap ETF (JHMM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JHMM
Edwards Lifesciences (EW) Q4 Earnings In Line, Revenues Top
by Zacks Equity Research
Edwards Lifesciences (EW) Q4 results benefit from growth in all the businesses.
Edwards Lifesciences (EW) Q4 Earnings Meet Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 0.00% and 0.41%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Earnings Lineup for Jan 31: EW, BAX & More
by Zacks Equity Research
Let's take a look at the factors that are likely to influence the earnings results of a few Medical Products bigwigs within the broader Medical space.
What's in Store for Edwards Lifesciences' (EW) Q4 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) expected to see consistent performance by Surgical Structural Heart and Critical Care segments in Q4.
Edwards Lifesciences (EW) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Edwards Lifesciences (EW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should John Hancock Multifactor Mid Cap ETF (JHMM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JHMM
Can Edwards Lifesciences (EW) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Edwards Lifesciences (EW) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Should John Hancock Multifactor Mid Cap ETF (JHMM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JHMM
Will Walgreens (WBA) Q1 Earnings Gain From Overall Strength?
by Zacks Equity Research
Several planned developments, early benefits from new pharmacy contracts as well as increased volumes are consistently driving growth within Walgreens Boots' (WBA) Retail Pharmacy USA division.
Edwards Lifesciences Advances in AI With Bay Labs Tie-Up
by Zacks Equity Research
Through the tie-up, Edwards Lifesciences (EW) aims at improving detection of heart diseases and enhancing quality by using Bay Labs' ability to apply AI to cardiovascular imaging.
Edwards Lifesciences' Critical Care Arm Solid, THVT View Dull
by Zacks Equity Research
Edwards Lifesciences (EW) sees strong Critical Care division sales. Management expects sluggish underlying THVT sales for 2018.
Edwards Lifesciences (EW) Up 5.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Edwards Lifesciences' CE Mark for SAPIEN 3 Boosts THVT Arm
by Zacks Equity Research
Latest CE Mark receipt is expected to fortify Edwards Lifesciences' (EW) position in Europe.
Edwards Lifesciences (EW) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Edwards Lifesciences (EW) closed the most recent trading day at $149.75, moving -1.99% from the previous trading session.
The Zacks Analyst Blog Highlights: Boeing, Texas Instruments, General Dynamics, American International, TD Ameritrade and Edwards Lifesciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Boeing, Texas Instruments, General Dynamics, American International, TD Ameritrade and Edwards Lifesciences